|
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor Clinical research trials and Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor. Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor clinical trial. Participants frequently get the best healthcare available for their Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
For Condition: Brain Tumor,Lymphoma
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Duke Comprehensive Cancer Center
Synopsis: RATIONALE: Determination of genetic markers for leukemia or non-Hodgkin's lymphoma that is secondary to Hodgkin's disease and childhood brain tumors may help doctors to identify patients who are at risk for these cancers. PURPOSE: Clinical trial to determine the presence of certain genes in patients who are receiving treatment for Hodgkin's disease or childhood brain tumors.
Details: OBJECTIVES: I. Determine the frequency of chromosome 3, 11, and 21 aberrations in peripheral blood lymphocytes (PBL) specifically associated with acute myelogenous leukemia in patients with adult or pediatric Hodgkin's disease treated with radiotherapy and/or chemotherapy. II. Determine the frequency of these aberrations in patients with pediatric central nervous system tumors treated with radiotherapy and/or chemotherapy. III. Determine the glutathione-S-transferase allotype, associated with human toxicological response to carcinogen exposure, for these patients. IV. Determine the frequency of t(14;18) gene rearrangement, associated with deregulation of the bcl-2 proto-oncogene in non-Hodgkin's lymphoma, in PBL of these patients. PROTOCOL OUTLINE: An extra tube of blood is collected before, every 4 weeks during, and every 3 months after radiotherapy and/or chemotherapy. DNA is isolated from the blood sample and the GSTM1, GSTT1, and various cytochrome P (CYP) 450 genotypes are determined by PCR. Mononuclear leukocytes are analyzed for chromosome aberrations on chromosome numbers 3, 11, and 21. Pretreatment karyotype and frequency of translocations are determined for each patient. Peripheral blood lymphocyte DNA is also examined for t(14;18) gene rearrangements. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 2 years.
Eligibility:
Study Type: Observational, Cross-Sectional
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of Hodgkin's disease; Adult or child OR Diagnosis of primary CNS malignancy; 16 and under; Medulloblastoma; Ependymoma; Brain stem glioma; Astrocytoma; Primitive neuroectodermal tumor (PNET) - Proposed therapy must include external beam radiotherapy and/or chemotherapy --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: See Disease Characteristics - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics - Surgery: Not specified --Patient Characteristics-- - Age: See Disease Characteristics; Any age - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
EdwardHalperin, Study Chair, Duke Comprehensive Cancer Center
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Additional Information:
Study ID Numbers: CDR0000067681; DUMC-IRB-086-97-1,NCI-G00-1840,DUMC-0113-99-1R2
Study Start Date: February 2000
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006342
Other Brain Tumor Studies:
1. Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
2. Melphalan in Patients With Neoplastic Meningitis
3. Procarbazine in Treating Patients With Recurrent Brain Tumor
4. Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
5. Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Related Studies:
Other Brain Tumor Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
|
|
|
|
|
|
|
|